MXPA02012409A - Derivados de pirrol para tratamiento del sida. - Google Patents
Derivados de pirrol para tratamiento del sida.Info
- Publication number
- MXPA02012409A MXPA02012409A MXPA02012409A MXPA02012409A MXPA02012409A MX PA02012409 A MXPA02012409 A MX PA02012409A MX PA02012409 A MXPA02012409 A MX PA02012409A MX PA02012409 A MXPA02012409 A MX PA02012409A MX PA02012409 A MXPA02012409 A MX PA02012409A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- aryl
- hydrogen
- heterocyclyl
- compounds
- Prior art date
Links
- 150000003233 pyrroles Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- -1 methyl-oxy-carbonyl Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La invencion se refiere a nuevos derivados de pirrol, un proceso para su fabricacion, composiciones farmaceuticas y el uso de tales compuestos en medicina. En particular, los compuestos de formula (I) son inhibidores del enzima transcriptasa inversa del virus de la inmunodeficiencia humana, que esta implicado en la replicacion virica. En consecuencia, los compuestos de esta invencion pueden utilizarse ventajosamente como agentes terapeuticos para el proceso mediado por el VIH. La invencion describe nuevos compuestos de formula (Ver formula I) en donde R1 es alquilo, cicloalquilo, arilo o heterociclilo; R2 es alquilo, cicloalquilo, arilo o heterociclilo; R3 es hidrogeno, alquilo, cicloalquilo, arilo o heterociclilo; R4 es hidrogeno, alquilo, carboxilo, C (=O)R, CONR' R", ciano o alquenilo, en donde R es hidrogeno, alquilo, alcoxi, trifluorometilo, metil-oxi-carbonilo o etil-oxi-carbonilo, y en donde R' y R", son de forma independiente, hidrogeno, alquilo o arilo; R5 es alquilo, arilo o un grupo -Z-C(=O)R''', en donde Z es un enlace sencillo o -CH=CH-, y en donde R''' es hidrogeno o alquilo; X representa S, S(O), S(0)2,O, N(alquilo) o X-R2 en conjunto representan CH2-arilo o CH2- heterociclilo; y con la condicion de que solamente uno de R3 y R4 es hidrogeno y el alquilo en R3 no es CF3; y esteres o eteres hidrolizables de los mismos o una sal farmaceuticamente aceptable de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0016453.3A GB0016453D0 (en) | 2000-07-04 | 2000-07-04 | Pyrrole derivatives |
| PCT/EP2001/004832 WO2002002524A1 (en) | 2000-07-04 | 2001-04-30 | Pyrrole derivatives for treating aids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012409A true MXPA02012409A (es) | 2003-04-25 |
Family
ID=9895031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012409A MXPA02012409A (es) | 2000-07-04 | 2001-04-30 | Derivados de pirrol para tratamiento del sida. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6737429B2 (es) |
| EP (1) | EP1301481A1 (es) |
| JP (1) | JP2004502674A (es) |
| KR (1) | KR100549884B1 (es) |
| CN (1) | CN1440385A (es) |
| AR (1) | AR028602A1 (es) |
| AU (2) | AU6387401A (es) |
| BR (1) | BR0112241A (es) |
| CA (1) | CA2412270A1 (es) |
| EC (1) | ECSP014109A (es) |
| GB (1) | GB0016453D0 (es) |
| GT (1) | GT200100111A (es) |
| MX (1) | MXPA02012409A (es) |
| PA (1) | PA8516201A1 (es) |
| PE (1) | PE20020269A1 (es) |
| UY (1) | UY26720A1 (es) |
| WO (1) | WO2002002524A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1405849A1 (en) * | 2002-10-04 | 2004-04-07 | Corning Incorporated | Halogenated styrene compounds and low-absorption-loss polymers obtainable therefrom |
| CA2801848C (en) * | 2003-12-26 | 2015-03-31 | Masatoshi Hagiwara | Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| CA2582777A1 (en) | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| TW200628446A (en) * | 2004-12-14 | 2006-08-16 | Takeda Pharmaceuticals Co | Substituted pyrrole derivative |
| EP1838679A1 (en) * | 2005-01-06 | 2007-10-03 | Pfizer Limited | Imidazole derivatives as enzyme reverse transcriptase modulators |
| BRPI0615111B8 (pt) | 2005-08-30 | 2021-05-25 | Takeda Pharmaceuticals Co | composto, composição farmacêutica, e, uso do composto |
| US20100113421A1 (en) * | 2006-10-06 | 2010-05-06 | Williams Theresa M | Non-nucleoside reverse transcriptase inhibitors |
| EP2099443A4 (en) * | 2006-11-10 | 2010-05-05 | Syndax Pharmaceuticals Inc | ASSOCIATION OF ERA + LIGANDS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF CANCER |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| WO2009015180A2 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| EP2179329A1 (en) * | 2007-10-16 | 2010-04-28 | Nikon Corporation | Illumination optical system, exposure apparatus, and device manufacturing method |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| NZ591793A (en) | 2008-08-27 | 2012-11-30 | Takeda Pharmaceutical | Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds |
| GB0823001D0 (en) * | 2008-12-17 | 2009-01-28 | Syngenta Participations Ag | Thiophene,furan and pyrrole derivatives with plant growth regulating properties |
| CN101775011B (zh) * | 2009-01-13 | 2013-07-31 | 中国人民解放军军事医学科学院毒物药物研究所 | N-取代苯基-3-甲烯杂环芳烃-2,5-二甲基吡咯类化合物及其抗hiv/aids的应用 |
| WO2021102114A1 (en) * | 2019-11-19 | 2021-05-27 | New York Blood Center, Inc. | Substituted heterocyclics with therapeutic activity in hiv |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3644631A (en) * | 1969-05-13 | 1972-02-22 | Endo Lab | Therapeutic methods utilizing aryl pyrrol-3-yl ketones |
| US4282242A (en) * | 1980-03-07 | 1981-08-04 | Pfizer Inc. | Antidiabetic pyrrolecarboxylic acids |
| US4347186A (en) * | 1980-10-20 | 1982-08-31 | Syntex (U.S.A.) Inc. | Process for preparing 5-aroyl 1,2-dihydro-3-H pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein |
| EP0674631B1 (en) * | 1992-12-17 | 1999-12-08 | Pfizer Inc. | Substituted pyrazoles as crf antagonists |
| CA2192208C (en) * | 1994-06-06 | 2002-09-10 | Pfizer Limited | Substituted pyrazoles |
| TW406075B (en) * | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
| CA2260213C (en) * | 1996-07-11 | 2005-03-29 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
| DE19963174A1 (de) * | 1999-12-27 | 2001-07-12 | Gruenenthal Gmbh | Substituierte Pyrrol-Mannichbasen |
-
2000
- 2000-07-04 GB GBGB0016453.3A patent/GB0016453D0/en not_active Ceased
-
2001
- 2001-04-30 CN CN01812290A patent/CN1440385A/zh active Pending
- 2001-04-30 AU AU6387401A patent/AU6387401A/xx active Pending
- 2001-04-30 BR BR0112241-0A patent/BR0112241A/pt not_active Withdrawn
- 2001-04-30 KR KR1020037000138A patent/KR100549884B1/ko not_active Expired - Fee Related
- 2001-04-30 CA CA002412270A patent/CA2412270A1/en not_active Abandoned
- 2001-04-30 AU AU2001263874A patent/AU2001263874B2/en not_active Ceased
- 2001-04-30 MX MXPA02012409A patent/MXPA02012409A/es active IP Right Grant
- 2001-04-30 WO PCT/EP2001/004832 patent/WO2002002524A1/en not_active Application Discontinuation
- 2001-04-30 JP JP2002507781A patent/JP2004502674A/ja active Pending
- 2001-04-30 EP EP01938137A patent/EP1301481A1/en not_active Withdrawn
- 2001-05-04 PA PA20018516201A patent/PA8516201A1/es unknown
- 2001-05-18 UY UY26720A patent/UY26720A1/es not_active Application Discontinuation
- 2001-05-22 AR ARP010102414A patent/AR028602A1/es not_active Application Discontinuation
- 2001-05-25 PE PE2001000487A patent/PE20020269A1/es not_active Application Discontinuation
- 2001-06-12 GT GT200100111A patent/GT200100111A/es unknown
- 2001-06-13 US US09/880,534 patent/US6737429B2/en not_active Expired - Fee Related
- 2001-07-04 EC EC2001004109A patent/ECSP014109A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6737429B2 (en) | 2004-05-18 |
| CA2412270A1 (en) | 2002-01-10 |
| EP1301481A1 (en) | 2003-04-16 |
| KR100549884B1 (ko) | 2006-02-06 |
| GB0016453D0 (en) | 2000-08-23 |
| AU2001263874B2 (en) | 2006-10-19 |
| UY26720A1 (es) | 2001-11-30 |
| PA8516201A1 (es) | 2002-07-30 |
| WO2002002524A1 (en) | 2002-01-10 |
| JP2004502674A (ja) | 2004-01-29 |
| US20020032221A1 (en) | 2002-03-14 |
| KR20030014321A (ko) | 2003-02-15 |
| AU6387401A (en) | 2002-01-14 |
| GT200100111A (es) | 2002-03-18 |
| PE20020269A1 (es) | 2002-04-08 |
| CN1440385A (zh) | 2003-09-03 |
| AR028602A1 (es) | 2003-05-14 |
| ECSP014109A (es) | 2002-02-25 |
| BR0112241A (pt) | 2003-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02012409A (es) | Derivados de pirrol para tratamiento del sida. | |
| MY146669A (en) | Pyrazole derivatives for treating hiv | |
| YU27203A (sh) | Pirazol derivati za tretiranje virusnih oboljenja | |
| HUP0105077A2 (hu) | Szerin-proteáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
| MY128463A (en) | 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
| IL180495A (en) | Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors | |
| DE60218511D1 (de) | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase | |
| WO2005103003A3 (en) | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors | |
| MXPA03011199A (es) | Derivados de pirazol como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih). | |
| DE60318874D1 (en) | Pyrazolderivate | |
| WO2005000840A8 (en) | Substituted diketopiperazines and their use as oxytocin antagonists | |
| HUP0203161A2 (hu) | Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AU2003263455A1 (en) | Pyrazole amides for treating hiv infections | |
| RS20080141A (en) | Inhibitors of the hiv integrase enzyme | |
| AU2003264940A1 (en) | Pyrazole derivatives and their use as therapeutic agents for hiv mediated diseases | |
| EA200500287A1 (ru) | Производные 4-(3, 5-дицианофенокси)пиразола для применения в качестве модуляторов обратной транскриптазы в лечении, в числе прочего, вич-инфекции | |
| ATE374775T1 (de) | Inhibitoren des hiv-integrase-enzyms | |
| AP1846A (en) | Pyrazole Derivatives. | |
| TNSN03088A1 (fr) | Derives de pyrazole pour le traitement d'une infection par le vih | |
| WO2005028442A3 (en) | 2-pyridinone derivatives, having hiv inhibiting properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |